SBI Securities’s Vaxcyte PCVX Stock Holding History

SBI Securities’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$58	Hold	1	–	–	﹤0.01%	3637
2026 Q1	$58	Hold	1	–	–	﹤0.01%	3542
2025 Q4	$46	Sell	1 -1	-50%	-$45	﹤0.01%	3588
2025 Q3	$72	Sell	2 -8	-80%	-$265	﹤0.01%	3610
2025 Q2	$325	Buy	10 +9	+900%	+$295	﹤0.01%	3143
2025 Q1	$38	Hold	1	–	–	﹤0.01%	3715
2024 Q4	$82	Buy	+1	New	+$99	﹤0.01%	3516

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

SBI Securities's PCVX Position: Q2 2026 in Review

SBI Securities held its Vaxcyte (PCVX) position steady in Q2 2026 at 1 share worth $58. The position accounts for ﹤0.01% of the portfolio, ranked #3637.

SBI Securities first reported a position in PCVX in Q4 2024 and has held it in 7 quarters since. The position peaked at $325 in Q2 2025. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

SBI Securities held 1 share of Vaxcyte worth $58 as of Q2 2026.
SBI Securities left its Vaxcyte share count unchanged in Q2 2026.
Vaxcyte made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3637 holding.
SBI Securities first reported a position in Vaxcyte in Q4 2024 and has held it in 7 quarters since.
SBI Securities's Vaxcyte position peaked at $325 in Q2 2025.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.